Cargando…

The safety of JAK-1 inhibitors

As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clarke, Benjamin, Yates, Mark, Adas, Maryam, Bechman, Katie, Galloway, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098103/ https://www.ncbi.nlm.nih.gov/pubmed/33950230 http://dx.doi.org/10.1093/rheumatology/keaa895

Ejemplares similares

The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
por: Bechman, Katie, et al.
Publicado: (2019)

The infection risks of JAK inhibition
por: Adas, Maryam A., et al.
Publicado: (2021)

Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]
por: Bechman, Katie, et al.
Publicado: (2020)

A systematic review and network meta-analysis of the safety of early interventional treatments in rheumatoid arthritis
por: Adas, Maryam A, et al.
Publicado: (2021)

JAK1 selective inhibitors for the treatment of spondyloarthropathies
por: White, Jonathan P E, et al.
Publicado: (2021)

Clinical use of Jak 1 inhibitors for rheumatoid arthritis
por: Nash, Peter
Publicado: (2021)

JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications
por: Agrawal, Manasi, et al.
Publicado: (2020)

Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

How important is JAK1 selectivity?
por: Edwards, Christopher J
Publicado: (2021)

JAK1 inhibition and inflammatory bowel disease
por: Harris, Clare, et al.
Publicado: (2021)

Efficacy of JAK inhibitors in Crohn’s Disease
por: Rogler, Gerhard
Publicado: (2020)

Efficacy of JAK inhibitors in Ulcerative Colitis
por: Ferrante, Marc, et al.
Publicado: (2020)

IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression
por: Tharmarajah, Emmanuel, et al.
Publicado: (2021)

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
por: Bechman, Katie, et al.
Publicado: (2020)

Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
por: Bechman, Katie, et al.
Publicado: (2020)

OA12 Grimey granulomas of sarcoidosis
por: Nagra, Deepak, et al.
Publicado: (2023)

Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease
por: Bechman, Katie, et al.
Publicado: (2023)

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
por: Russell, Mark D, et al.
Publicado: (2023)

A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
por: Nagra, Deepak, et al.
Publicado: (2023)

Data quality predicts care quality: findings from a national clinical audit
por: Yates, Mark, et al.
Publicado: (2020)

The immunosuppressed traveler: infection risks with autoimmunity and immunosuppression, vaccinations, and general travel advice
por: Allen, Victoria, et al.
Publicado: (2020)

Diagnostic delay is common for patients with axial spondyloarthritis: results from the National Early Inflammatory Arthritis Audit
por: Russell, Mark D, et al.
Publicado: (2021)

Corrigendum to: Diagnostic delay is common for patients with axial spondyloarthritis: results from the National Early Inflammatory Arthritis Audit
por: Russell, Mark D, et al.
Publicado: (2021)

Updates on the Treatment of Essential Hypertension: A Summary of AHRQ’s Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Direct Renin Inhibitors
por: Powers, Benjamin, et al.
Publicado: (2011)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

Waiting for JAK inhibitor safety data
por: Kragstrup, Tue Wenzel, et al.
Publicado: (2022)

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety
por: Atchison, James W., et al.
Publicado: (2013)

Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies
por: Gower, Richard G, et al.
Publicado: (2011)

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
por: Iznardo, Helena, et al.
Publicado: (2023)

Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
por: Handelsman, Yehuda, et al.
Publicado: (2018)

Implementation of patient safety strategies in European hospitals
por: Suñol, R, et al.
Publicado: (2009)

Accelerating progress towards universal health coverage in Asia and Pacific: improving the future for women and children
por: Beattie, Allison, et al.
Publicado: (2016)

Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial
por: Bechman, Katie, et al.
Publicado: (2018)

A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis
por: Bechman, Katie, et al.
Publicado: (2020)

Oral surveillance and JAK inhibitor safety: the theory of relativity
por: Winthrop, Kevin L., et al.
Publicado: (2022)

Do European hospitals have quality and safety governance systems and structures in place?
por: Shaw, C, et al.
Publicado: (2009)

Annual changes in the Fukushima residents’ views on the safety of water and air environments and their associations with the perception of radiation risks
por: Suzuki, Satoshi, et al.
Publicado: (2018)

Learning from MARQuIS: future direction of quality and safety in hospital care in the European Union
por: Groene, O, et al.
Publicado: (2009)

JAK1 Selective inhibitors
por: Edwards, Christopher
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ht4ta3a3ohsh617k7tjp9jaq29